Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 8, 2009, Pages 1517-1521

  Campos, Alline Cristina ^a   Guimarães, Francisco Silveira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anxiety; Cannabidiol; Capsazepine; Central gray; WIN 55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABIDIOL; CAPSAZEPINE; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; EXPLORATORY BEHAVIOR; LOW DRUG DOSE; MALE; MAZE TEST; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PROTEIN FUNCTION; RAT; TRANQUILIZING ACTIVITY;

ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; ARACHIDONIC ACIDS; BENZOXAZINES; CAPSAICIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; MALE; MICROINJECTIONS; MORPHOLINES; NAPHTHALENES; PERIAQUEDUCTAL GRAY; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; TIME FACTORS; TRPV CATION CHANNELS;

EID: 71549171421     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.08.017     Document Type: Article

References (47)

1. Aguiar D.C., Terzian A.L., Guimarães F.S., and Moreira F.A. Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. Psychopharmacology (Berl) 205 (2009) 217-225
2. Arévalo C., De Miguel R., and Hernandez-Trista'n R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 70 (2000) 123-131
3. Berrendero F., and Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by delta (9)-tetrahydrocannabinol. Psychopharmacology(Berl) 163 (2002) 111-117
4. Bisogno T., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134 (2001) 845-852
5. Calignano A., La Rana G., Giuffrid A., and Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 394 (1998) 277-281
6. Campos A.C., and Guimarães F.S. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) 199 (2008) 223-230
7. Carobrez A.P., and Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 29 (2005) 1193-1205
8. Caterina M.J., et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288 (2000) 306-313
9. Caterina M.J., et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
10. Cristino L., et al. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139 (2006) 1405-1415
11. Dewey W.L., et al. Cannabinoid pharmacology. Pharmacol Rev 38 2 (1986) 151-178
12. Ferrari F., Ottani A., Vivoli R., and Giuliani D. Learning impairment produced in rats by the cannabinoid agonist HU 210 in a water-maze task. Pharmacol Biochem Behav 64 (1999) 555-561
13. File S.E. Behavioural detection of anxiolytic action. In: Elliott J.M., Heal D.J., and Marsden C.A. (Eds). Experimental approaches to anxiety and depression (1992), Wiley, New York 25-44
14. Genn R.F., Tucci S., Marco E., Viveros M.P., and File S.E. Anxiolytic and anxiogenic effects of the cannabinoid agonist CP 55, 940 animal tests of anxiety. J Psychopharmacol 17 (2003) A27
15. Giuliani D., Ferrari F., and Ottani A. The cannabinoid agonist HU 210 modifies rat behavioural responses to novelty and stress. Pharmacol Res 41 1 (2000) 47-53
16. Guimarães F.S., et al. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 100 4 (1990) 558-559
17. Guimarães F.S., Carobrez A.P., De Aguiar J.C., and Graeff F.G. Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology (Berl) 103 (1991) 91-94
18. Hajos N., and Freund T.F. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43 (2002) 503-510
19. Hajos N., et al. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12 (2000) 3239-3249
20. Hajos N., Ledent C., and Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106 (2001) 1-4
21. Herkenham M., et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11 (1991) 563-583
22. Jeske N.A., et al. Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons. J Biol Chem 281 43 (2006) 32879-32890
23. Kofalvi A., Vizi E.S., Ledent C., and Sperlagh B. Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. Eur J Neurosci 18 (2003) 1973-1978
24. Ledent C., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
25. Lichtman A.H., and Martin B.R. Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism. Brain Res 559 (1991) 309-314
26. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
27. Mezey E., et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A 97 (2000) 3655-3660
28. Molchanov M.L., and Guimarães F.S. Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats. Psychopharmacology (Berl) 160 (2002) 30-38
29. Moraes C.L., Bertoglio L.J., and Carobrez A.P. Interplay between glutamate and serotonin within the dorsal periaqueductal gray modulates anxiety-related behavior of rats exposed to the elevated plus-maze. Behav Brain Res 194 (2008) 181-186
30. Moreira F.A., Aguiar D.C., and Guimarães F.S. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 52 (2007) 958-965
31. Nilius B., and Voets T. TRP channels: a TR(I)P through a world of multifunctional cation channels. Pflugers Arch 451 (2005) 1-10
32. Onaivi E.S., Green M.R., and Martin B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253 (1990) 1002-1009
33. Palazzo E., et al. Interaction between vanilloid and glutamate receptors in the central modulation of nociception. Eur J Pharmacol 439 (2002) 69-75
34. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1997), Academic Press, New York
35. Pertwee R.G. Pharmacological actions of cannabinoids. Handb Exp Pharmacol (2005) 1-51
36. Pertwee R.G. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 30 (2006) S13-S18
37. Reibaud M., et al. Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur J Pharmacol 379 (1999) R1-R2
38. Rodriguez de Fonseca F., Rubio P., Menzaghi F., Merlo-Pich E., Rivier J., Koob G.F., et al. Corticotropin-releasing factor (CRF) antagonist [Dhe12,Nle21,38, CaMeLeu37] CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 276 (1996) 56-64
39. Rubino T., et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex. 18 6 (2008) 1292-1301
40. Rubino T., et al. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 54 1 (2008) 151-160
41. Russo E.B., Burnett A., Hall B., and Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30 (2005) 1037-1043
42. Terzian A.L., Aguiar D.C., Guimarães F.S., and Moreira F.A. Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. Eur Neuropsychopharmacol 19 (2009) 188-195
43. Tominaga M., et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21 (1998) 531-543
44. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
45. Viveros M.P., Marco E.M., and File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81 (2005) 331-342
46. Vriens J., Janssens A., Prenen J., Nilius B., and Wondergem R. TRPV channels and modulation by hepatocyte growth factor/scatter factor in human hepatoblastoma (HepG2) cells. Cell Calcium 36 1 (2004) 19-28
47. Xing J., and Li J. TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dlPAG) neurons. J Neurophysiol 97 (2007) 503-511